PHIO Company Profile and Key Details

Q: Who are the executives of PHIO?

Ms. Linda M. MahoneySenior Vice President of Devel.Ms. Caitlin KontulisVice President of Fin. & Admin. and Sec.Mr. Robert J. BittermanPres, Chief Executive Officer & Chairman

NASDAQ : PHIO

Phio Pharmaceuticals

$1.22

0.04+3.39%

At Close 4:00 PM

56.64

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Phio Pharmaceuticals Corp. (PHIO) stock declined over -6.56%, trading at $1.14 on NASDAQ, down from the previous close of $1.22. The stock opened at $1.22, fluctuating between $1.13 and $1.22 in the recent session.

Stock Snapshot

1.22

Prev. Close

13.24M

Market Cap

1.13

Day Low

-0.79

P/E Ratio

-1.45

EPS (TTM)

-2.87

Cash Flow per Share

1.22

Open

11.62M

Number of Shares

1.22

Day High

98.46%

Free Float in %

2.06

Book Value

310.88K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	1.21	1.23	1.19	1.22	80.43K
Apr 29, 2026	1.20	1.21	1.18	1.18	62.06K
Apr 28, 2026	1.21	1.22	1.20	1.20	61.31K
Apr 27, 2026	1.18	1.22	1.18	1.21	85.86K
Apr 23, 2026	1.26	1.26	1.22	1.23	186.06K
Apr 22, 2026	1.24	1.27	1.24	1.25	80.82K
Apr 21, 2026	1.26	1.27	1.24	1.25	92.82K
Apr 20, 2026	1.30	1.30	1.25	1.27	90.09K
Apr 17, 2026	1.29	1.31	1.27	1.29	102.89K
Apr 16, 2026	1.33	1.34	1.27	1.27	144.24K
Apr 14, 2026	1.22	1.30	1.22	1.29	238.29K
Apr 13, 2026	1.21	1.27	1.20	1.24	161.45K
Apr 10, 2026	1.24	1.26	1.21	1.21	184.73K
Apr 09, 2026	1.25	1.28	1.25	1.25	59.91K
Apr 08, 2026	1.30	1.30	1.25	1.30	130.36K
Apr 07, 2026	1.27	1.27	1.24	1.24	83.34K
Apr 06, 2026	1.26	1.29	1.24	1.26	157.29K
Apr 02, 2026	1.26	1.31	1.26	1.28	91.98K
Apr 01, 2026	1.22	1.35	1.22	1.30	473.76K
Mar 31, 2026	1.21	1.27	1.21	1.22	205.49K

Contact Details

Marlborough, MA 01752

United States

https://www.phiopharma.com 508 767 3861

About Company

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) closed at $1.14 USD, losing -$0.08 (-6.56%) from the previous close of $1.22. The stock is currently mid-range between its 52-week high and low $0.81 and $4.19. With a market capitalization of about $13.24 million, Phio Pharmaceuticals Corp. is classified as a micro-cap and shows market-like volatility (beta ~0.81). Key stats such as the average daily volume over the past year has been around 3.71 million shares, volume is running light vs its 52-week average. Headquartered in Marlborough, MA, Phio Pharmaceuticals Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert J. Bitterman, the company employs approximately 5 people and listed since May 10, 2012. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -2.27%, SMA50 -2.31%, SMA200 -41.06%). The stock’s 14-day RSI is 47.92 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.46% below its high and over 31.66% above its low. Average 10-day trading volume of 92.76 thousand shares is below the 3-month average of 3.95 million, indicating normal recent market interest.

Valuation Metrics

Phio Pharmaceuticals Corp. trades at a P/E ratio of -1.62, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.7 suggesting the stock is closer to book value. The P/FCF stands at -1.76, also below market averages.

Dividend & Fair Value

Phio Pharmaceuticals Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.51. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Phio Pharmaceuticals Corp. generated EPS of -$2.24 over the past year. Five-year average earnings growth is 66.3%. Wall Street analysts project EPS growth of 59.13% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $14.00. The high target offers 1047.54% upside. The low target suggests 1047.54% downside. The mean target is $14.00. This offers 1047.54% upside. Phio Pharmaceuticals Corp. earnings surprise history is frequent misses against expectations. The quarter that ended March 05, 2026, missed forecasts by -55.88%. The prior quarter beat by -2.22%. Over the last six quarters, Apple has recorded several small beats. These include -21.13% in August 14, 2024.

Shareholding & Insider Activity

Phio Pharmaceuticals Corp. has 5.73 million shares outstanding. The public float is 5.68 million shares, elevated short interest at 5.11% of float. This equals 290.43 thousand shares. The short ratio is 1.76 days. Institutional investors hold 10.34% of the float. Insiders own 0.96%. Advanced RNA Technologies, LLC holds 1.22 million shares, Eliseev Alexey has 950.31 thousand shares and Bitterman Robert J has 291.42 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Phio Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -115.61% and ROE at -140.05%.
On valuation metrics, Phio Pharmaceuticals trades at a P/E of -1.62, P/S of 0.00 and P/B of 0.70. The current ratio is 49.37 and quick ratio is 49.37. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -147.42 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Phio Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $184.00K (margin 0.00%). Operating income was - $10.70M (margin 0.0%). Net income was- $10.83M (EPS - $5.20).
The company ended the quarter with $8.49M in cash and short-term investments, a total debt of $35.00K, and net debt of - $8.46M. Total assets were $9.36M, with equity of $7.73M. Financials further reflected weakness, with operating cash flow of - $10.75M, free cash flow of - $10.75M, and capital expenditures of - $5.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Phio Pharmaceuticals Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.1%, with price expected at $1.17 by May 14, 2026, within a range of $1.13 to $1.20 3-Month Outlook: Projected rise of 129.51%, reaching $2.80 by July 29, 2026, with a range of $2.49 to $3.03. 1-Year Outlook: Projected loss of -40.98%, with price at $0.72 by April 30, 2027, within a range of $0.03 to $1.03.

Key Takeaways

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares are flat 2.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Phio Pharmaceuticals Corp. trading at a premium to the broader market with a P/E of -1.62. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.00, suggesting 555.74% upside. Our AI forecast model points to short-term weakness (-4.1% over two weeks), a medium-term rise (129.51% over three months), and a longer-term loss (-40.98% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Phio Pharmaceuticals Corp. (PHIO) stock price?

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) stock price is $1.14 in the last trading session. During the trading session, PHIO stock reached the peak price of $1.22 while $1.13 was the lowest point it dropped to. The percentage change in PHIO stock occurred in the recent session was -6.56% while the dollar amount for the price change in PHIO stock was - $0.08.

PHIO's industry and sector of operation?

The NASDAQ listed PHIO is part of Biotechnology industry that operates in the broader Healthcare sector. Phio Pharmaceuticals Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PHIO?

Ms. Linda M. Mahoney
Senior Vice President of Devel.
Ms. Caitlin Kontulis
Vice President of Fin. & Admin. and Sec.
Mr. Robert J. Bitterman
Pres, Chief Executive Officer & Chairman

How PHIO did perform over past 52-week?

PHIO's closing price is 50.06% higher than its 52-week low of $0.81 where as its distance from 52-week high of $4.19 is -70.88%.

How many employees does PHIO have?

Number of PHIO employees currently stands at 5.

Link for PHIO official website?

Official Website of PHIO is: https://www.phiopharma.com

How do I contact PHIO?

PHIO could be contacted at phone 508 767 3861 and can also be accessed through its website. PHIO operates from 257 Simarano Drive, Marlborough, MA 01752, United States.

How many shares of PHIO are traded daily?

PHIO stock volume for the day was 310.88K shares. The average number of PHIO shares traded daily for last 3 months was 3.71M.

What is the market cap of PHIO currently?

The market value of PHIO currently stands at $13.24M with its latest stock price at $1.14 and 11.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.81
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PHIO Company Profile and Key Details

Phio Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook